Calcium Is a Key Signaling Molecule in beta -Lapachone-mediated Cell Death*

Colleen TagliarinoDagger §, John J. PinkDagger , George R. Dubyak, Anna-Liisa Nieminen||, and David A. BoothmanDagger **

From the Dagger  Departments of Radiation Oncology and Pharmacology, || Department of Anatomy, and the  Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio 44106-4942

Received for publication, January 25, 2001, and in revised form, March 1, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

beta -Lapachone (beta -Lap) triggers apoptosis in a number of human breast and prostate cancer cell lines through a unique apoptotic pathway that is dependent upon NQO1, a two-electron reductase. Downstream signaling pathway(s) that initiate apoptosis following treatment with beta -Lap have not been elucidated. Since calpain activation was suspected in beta -Lap-mediated apoptosis, we examined alterations in Ca2+ homeostasis using NQO1-expressing MCF-7 cells. beta -Lap-exposed MCF-7 cells exhibited an early increase in intracellular cytosolic Ca2+, from endoplasmic reticulum Ca2+ stores, comparable to thapsigargin exposures. 1,2-Bis-(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester, an intracellular Ca2+ chelator, blocked early increases in Ca2+ levels and inhibited beta -Lap-mediated mitochondrial membrane depolarization, intracellular ATP depletion, specific and unique substrate proteolysis, and apoptosis. The extracellular Ca2+ chelator, EGTA, inhibited later apoptotic end points (observed >8 h, e.g. substrate proteolysis and DNA fragmentation), suggesting that later execution events were triggered by Ca2+ influxes from the extracellular milieu. Collectively, these data suggest a critical, but not sole, role for Ca2+ in the NQO1-dependent cell death pathway initiated by beta -Lap. Use of beta -Lap to trigger an apparently novel, calpain-like-mediated apoptotic cell death could be useful for breast and prostate cancer therapy.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

beta -Lap1 is a naturally occurring compound present in the bark of the South American Lapacho tree. It has antitumor activity against a variety of human cancers, including colon, prostrate, promyelocytic leukemia, and breast (1-3). beta -Lap was an effective agent (alone and in combination with taxol) against human ovarian and prostate xenografts in mice, with little host toxicity (4). We recently demonstrated that beta -Lap kills human breast and prostate cancer cells by apoptosis, a cytotoxic response significantly enhanced by NAD(P)H:quinone oxidoreductase (NQO1, E.C. 1.6.99.2) enzymatic activity (5).2 beta -Lap cytotoxicity was prevented by co-treatment with dicumarol (an NQO1 inhibitor) in NQO1-expressing breast and prostate cancer cells (5).2 NQO1 is a cytosolic enzyme elevated in breast cancers (6) that catalyzes a two-electron reduction of quinones (e.g. beta -Lap, menadione), utilizing either NADH or NADPH as electron donors. Reduction of beta -Lap by NQO1 presumably leads to a futile cycling of the compound, wherein the quinone and hydroquinone form a redox cycle with a net concomitant loss of reduced NAD(P)H (5).

Apoptosis is an evolutionarily conserved pathway of biochemical and molecular events that underlie cell death processes involving the stimulation of intracellular zymogens. The process is a genetically programmed form of cell death involved in development, normal turnover of cells, and in cytotoxic responses to cellular insults. Once apoptosis is initiated, biochemical and morphological changes occur in the cell. These changes include: DNA fragmentation, chromatin condensation, cytoplasmic membrane blebbing, cleavage of apoptotic substrates (e.g. PARP, lamin B), and loss of mitochondrial membrane potential with concomitant release of cytochrome c into the cytoplasm (7-9). Apoptosis is a highly regulated, active process that requires the participation of endogenous cellular enzymes that systematically dismantle the cell. The most well characterized proteases in apoptosis are caspases, aspartate-specific cysteine proteases, that work through a cascade that can be initiated by mitochondrial membrane depolarization leading to the release of cytochrome c and Apaf-1 into the cytoplasm (10), that then activates caspase 9 (11). Non-caspase-mediated pathways are less understood.

We previously showed that apoptosis following beta -Lap administration was unique, in that an ~60-kDa PARP cleavage fragment, as well as distinct intracellular proteolytic cleavage of p53, were observed in NQO1-expressing breast or prostate cancer cells (5).2 These cleavage events were distinct from those observed when caspases were activated by topoisomerase I poisons, staurosporine, or administration of granzyme B (5, 12, 13). Furthermore, beta -Lap-mediated cleavage events were blocked by administration of global cysteine protease inhibitors, as well as extracellular Ca2+ chelators (12). Based on these data, we concluded that beta -Lap exposure of NQO1-expressing breast and prostate cancer cells caused the activation of a Ca2+-dependent protease with properties similar to calpain; in particular, the p53 cleavage pattern of beta -Lap-exposed cells was remarkably similar to the pattern observed after calpain activation (14, 15).

Ca2+ is recognized as an important regulator of apoptosis (16-21). The cytoplasmic Ca2+ concentration is maintained at ~100 nM in resting cells by relatively impermeable cell membranes, active extrusion of Ca2+ from the cell by plasma membrane Ca2+-ATPases, plasma membrane Na+/Ca2+ exchangers, and active uptake of cytosolic Ca2+ into the endoplasmic reticulum (ER) by distinct Ca2+-ATPases. In contrast, the concentration of Ca2+ in the extracellular milieu and in the ER is much higher (in the millimolar range). Evidence for involvement of Ca2+ influx into the cytosol as a triggering event for apoptosis has come from studies with specific Ca2+ channel blockers that abrogate apoptosis in regressing prostate following testosterone withdrawal (22). Other support for the involvement of Ca2+ in apoptosis comes from the observation that agents that directly mobilize Ca2+ (e.g. Ca2+ ionophores or the sarcoplasmic reticulum Ca2+-ATPase pump inhibitor, thapsigargin, TG) can trigger apoptosis in diverse cell types (23-27). Inhibition of the sarcoplasmic reticulum Ca2+-ATPase pump by TG causes a transient increase in cytoplasmic Ca2+ from ER Ca2+ stores, and a later influx of Ca2+ from the extracellular milieu, leading to the induction of apoptotic cell death (24, 27, 28). Consequently, emptying of intracellular Ca2+ stores may trigger apoptosis by disrupting the intracellular architecture and allowing key elements of the effector machinery (e.g. Apaf-1) to gain access to their substrates (e.g. caspase 9). Ca2+ has also been shown to be necessary for apoptotic endonuclease activation, eliciting DNA cleavage after many cellular insults (29-31). Buffering intracellular Ca2+ released from stored Ca2+ pools (e.g. ER) with BAPTA-AM, or removal of extracellular Ca2+ with EGTA, can protect cells against apoptosis (32, 33). Therefore, increases in intracellular Ca2+ levels appear to be important cell death signals in human cancer cells that might be exploited for anti-tumor therapy. Finally, Ca2+ may act as a signal for apoptosis by directly activating key proapoptotic enzymes (e.g. calpain); however, these proteolytic responses are poorly understood. The role of Ca2+ in cell death processes involving caspase activation has been examined in detail (28, 34-36). However, the role of Ca2+ in non-caspase-dependent cell death responses is relatively unexplored.

Recent studies have suggested that alterations in mitochondrial homeostasis play an essential role in apoptotic signal transduction induced by cytotoxic agents (37, 38). Various apoptotic stimuli have been shown to induce mitochondrial changes, resulting in release of apoptogenic factors, apoptosis-inducing factor (39), and mitochondrial cytochrome c (9) into the cytoplasm. These changes are observed during the early phases of apoptosis in human epithelial cells, and were linked to the initial cascade of events, sending the cell to an irreversible suicide pathway. During high, sustained levels of cytosolic Ca2+, mitochondrial Ca2+ uptake is driven by mitochondrial membrane potential to maintain Ca2+ homeostasis in the cytosol. In de-energized mitochondria, Ca2+ can be released by a reversal of this uptake pathway (40). These data, therefore, linked changes in Ca2+ homeostasis and mitochondrial membrane potential to the initiation of apoptosis. Li et al. (41) reported that beta -Lap caused a decrease in mitochondrial membrane potential with release of cytochrome c into the cytoplasm in a number of human carcinoma cell lines, shortly after drug addition. Other alterations in metabolism (e.g. ATP depletion) have not been examined in beta -Lap-treated cells.

We previously characterized the activation of a novel cysteine protease in various breast cancer cell lines with properties similar to the Ca2+-dependent cysteine protease, calpain, after exposure to beta -Lap (12). Using NQO1-expressing breast cancer cells, we show that beta -Lap elicits a rise in intracellular Ca2+ levels shortly after drug administration that eventually leads to apoptosis. This paper suggests a critical, but not sufficient, role for Ca2+ in the cell death pathway initiated by NQO1-dependent bioactivation of beta -Lap. Possible combinatorial effects (e.g. NAD(P)H depletion as well as intracellular calcium alterations) that initiate beta -Lap-mediated apoptosis in NQO1-expressing breast cancer cells will be discussed.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents-- beta -Lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2b]pyran-5,6-dione) was synthesized by Dr. William G. Bornmann (Memorial Sloan Kettering, New York), dissolved in dimethyl sulfoxide at 10 mM, and the concentration verified by spectrophotometric analysis (2, 5). EGTA, Hoescht 33258, and thapsigargin were obtained from Sigma. BAPTA-AM (1,2-bis-(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra-(acetoxymethyl ester)) was obtained from Calbiochem (La Jolla, CA). JC-1 (5,5'6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanine iodide) and Fluo-4-AM were obtained from Molecular Probes, Inc. (Eugene, OR).

Cell Culture-- MCF-7:WS8 (MCF-7) human breast cancer cells were obtained from Dr. V. Craig Jordan, (Northwestern University, Chicago, IL). MDA-MB-468 cells were obtained from the American Type Culture Collection and transfected with NQO1 cDNA in the pcDNA3 constitutive expression vector as described previously (5). Tissue culture components were purchased from Life Technologies, Inc., unless otherwise stated. MCF-7 cells were grown in RPMI 1640 cell culture medium supplemented with 10% fetal bovine serum, in a 37 °C humidified incubator with 5% CO2, 95% air atmosphere as previously described (2, 5). For all experiments, log-phase breast cancer cells were exposed to 5 µM beta -Lap for 4 h (unless otherwise indicated), after which fresh medium was added and cells were harvested at various times post-treatment.

TUNEL Assay-- Cells were seeded at 1 × 106 cells/10-cm Petri dish and allowed to grow for 24 h. Log-phase cells were then pretreated for 30 min with 10 µM BAPTA-AM, 3 mM EGTA, or 50 µM dicumarol followed by a 4-h pulse of 5 µM beta -Lap, as described above, or 24 h treatment of 10 µM ionomycin or 1 µM staurosporine. Medium was collected from experimental as well as control conditions 24 h later, and attached along with floating cells were monitored for apoptosis using TUNEL 3'-biotinylated DNA end labeling via the APO-DIRECT kit (Pharmingen, San Diego, CA) as described (5). Apoptotic cells were analyzed and quantified using an EPICS XL-MCL flow cytometer that contained an air-cooled argon laser at 488 nm, 15 mW (Beckman Coulter Electronics; Miami, Fl), and XL-MCL acquisition software provided with the instrument.

Cell Growth Assays-- MCF-7 cells were seeded at 5 × 104 cells per well in a 12-well plate and allowed to attach overnight. The following day, log-phase cells were pretreated for 30 min with 5 µM BAPTA-AM, followed by a 4-h pulse of beta -Lap (0-5 µM). Drugs were removed and fresh medium added. Cells were allowed to grow for an additional 6 days. DNA content (a measure of cell growth) was determined by fluorescence using Hoechst dye 33258 as described (5) and changes in growth were monitored using a PerkinElmer HTS 7000 Plus Bio Assay Plate Reader (Norwalk, CT) with 360 and 465 nm excitation and emission filters, respectively. Data were expressed as relative growth, T/C (treated/control), using experiments performed at least twice.

Confocal Microscopy-- MCF-7 cells were seeded at 2-3 × 105 cells per 35-mm glass bottom Petri dishes (MatTek Corp., Ashland, MA) and allowed to attach overnight. Cells were rinsed twice in a Ca2+/Mg2+ balanced salt solution (BSS, 130 mM NaCl, 5 mM KCl, 1.5 mM CaCl2, 1 mM MgCl2, 25 mM HEPES, pH 7.5, 5 mM glucose, 1 mg/ml bovine serum albumin) and loaded with the Ca2+-sensitive fluorescent indicator, fluo-4-AM (5 µM), in BSS for ~20-30 min at 37 °C. Cells were rinsed twice in BSS and incubated for an additional 20 min at 37 °C to allow for hydrolysis of the AM-ester. Cells were imaged with a Zeiss 410 confocal microscope (Thornwood, NY) equipped with a ×63 N.A. 1.4 oil immersion planapochromat objective at room temperature (the same results were observed at room temperature and 37 °C). Confocal images of fluo-4 fluorescence were collected using a 488-nm excitation light from an argon/krypton laser, a 560-nm dichroic mirror, and a 500-550 nm band-pass barrier filter. Three basal images were collected before drug addition (8 µM beta -Lap, ± 50 µM dicumarol or 200 nM TG). The mean pixel intensity was set to equal one for analyses of fold-increase in fluo-4 fluorescence intensity. Subsequently, images were collected after the indicated treatments at 90-s intervals. BAPTA-AM (20 µM) was co-loaded with fluo-4-AM where indicated. Mean pixels were determined in regions of interest for individual cells at each time point.

Mitochondrial Membrane Potential Determinations-- MCF-7 cells were seeded at 2.5-3 × 105 cells per 6-well plate, and allowed to grow for 24 h. Log-phase cells were pretreated for 30 min with 10 µM BAPTA-AM, 3 mM EGTA, or 50 µM dicumarol followed by a 4-h pulse of 5 µM beta -Lap, unless otherwise indicated. Cells were trypsinized and resuspended in phenol red-minus RPMI medium for analyses. Cells were maintained at 37 °C for the duration of the experiment, including during analyses. Prior to analyses, cells were loaded with 10 µg/ml JC-1 for 9-14 min and samples were analyzed using a Beckman Coulter EPICS Elite ESP (Miami, FL) flow cytometer. JC-1 monomer and aggregate emissions were excited at 488 nM and quantified using Elite acquisition software after signal collection through 525- and 590-nm band pass filters, respectfully. Shifts in emission spectra were plotted on bivariant dot plots, on a cell-by-cell basis, to determine relative mitochondrial membrane potential of treated and control cells.

ATP Measurements-- Cells were seeded at 2.5 × 105 cells per well in 6-well dishes and allowed to attach for 24 h. Fresh medium was added to the cells along with Ca2+ chelators or dicumarol 30 min prior to beta -Lap exposure (4 h unless otherwise indicated). Floating cells were collected, pelleted, and lysed in 1.67 M perchloric acid. Attached cells were lysed directly in 1.67 M perchloric acid. Following a 20-min incubation at room temperature, attached cells were scraped and transferred to corresponding microcentrifuge tube, cooled on ice for several minutes, and spun to pellet protein precipitates. Deproteinized samples were neutralized with 3.5 M KOH and HEPES/KOH (25 mM HEPES, 15 mM KOH, pH 8), and incubated on ice for 15 min. Precipitates were removed by centrifugation and samples stored at -20 °C. Cell extracts were analyzed for ATP and ADP levels using a luciferase-based bioluminescent assay and rephosphorylation protocols, as described (42).

Western Blot Analyses-- Whole cell extracts from control or beta -Lap-exposed MCF-7 cells were prepared and analyzed by SDS-polyacrylamide gel electrophoresis/Western blot analyses as previously described (2, 5, 12). Loading equivalence and transfer efficiency were monitored by Western blot analyses of proteins that are known to be unaltered by experimental treatments (2), and using Ponceau S staining of the membrane, respectively. Probed membranes were then exposed to x-ray film for an appropriate time and developed. Dilutions of 1:10,000 for the C-2-10 anti-PARP antibody (Enzyme Systems Products, Livermore, CA), and 1:2000 for anti-p53 DO-1 and anti-lamin B (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies were used as described (2, 12).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ca2+ Chelators Prevent beta -Lap-induced Apoptotic DNA Fragmentation and Protect against Cell Death-- Log-phase MCF-7 cells were treated for 4 h with 5 µM beta -Lap, fresh medium was then applied, and cells were harvested 24 h later and analyzed for DNA fragmentation (i.e. apoptotic cells staining positive in a TUNEL assay). Treatment of MCF-7 cells with beta -Lap resulted in >90% apoptotic cells (Fig. 1, A and B). However, MCF-7 cells exposed to a 30-min pretreatment with 10 µM BAPTA-AM or 3 mM EGTA, followed by a 4-h pulse of 5 µM beta -Lap, exhibited only 20 or 39% apoptotic cells, respectively, in 24 h.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 1.   beta -Lap-mediated apoptosis and relative cell growth is Ca2+-dependent. DNA fragmentation was assessed using the TUNEL assay. Log phase MCF-7 cells were treated with the indicated Ca2+ chelator for 30 min prior to a 4-h pulse of 5 µM beta -Lap. TUNEL assays were performed to monitor apoptosis 24 h after beta -Lap addition (A and B). A, shown are the results of any one experiment from studies performed at least three times. The number in the upper right corner represents percent cells staining positive in the TUNEL assay. Results are graphically summarized in B as the average of at three independent experiments, mean ± S.E. Student's t test for paired samples, experimental group compared with MCF-7 cells treated with beta -Lap alone are indicated (* p < 0.01). C, cells were exposed to a 4-h pulse of various concentrations of beta -Lap either alone (closed), or after a 30-min pretreatment with 5 µM BAPTA-AM (open). Relative DNA per well was determined by Hoescht 33258 fluorescence, and graphed as relative growth (treated/control DNA); mean relative DNA per well, ± S.E. Shown are representative results of experiments performed at least twice. Student's t test for paired samples, experimental group compared with MCF-7 cells treated with beta -Lap alone are indicated (*, p < 0.05; and **, p < 0.005).

To examine whether BAPTA-AM could affect beta -Lap lethality, we measured relative growth of MCF-7 cells with or without exposure to beta -Lap, and in the presence or absence of BAPTA-AM. MCF-7 cells were treated for 30 min with 5 µM BAPTA-AM, subsequently exposed to a 4-h pulse of beta -Lap (1.5-5 µM), and relative cell growth was measured 6 days later (Fig. 1C). The LD50 dose of beta -Lap in MCF-7 cells was ~2.5 µM in colony forming assays, which correlated well with IC50 relative growth inhibition, as measured by DNA content (2, 5). At 1.5 µM beta -Lap, cells exhibited little or no toxicity. At beta -Lap doses of 3 or 5 µM, cells exhibited considerable toxicity, >90% growth inhibition, as previously reported (2, 5). Toxicity was significantly prevented by 5 µM BAPTA-AM pretreatment. BAPTA-AM pretreated cells exhibit only 44 and 73% growth inhibition after 3 or 5 µM beta -Lap treatments, respectively (Fig. 1C). BAPTA alone did not affect MCF-7 cell growth compared with untreated controls.

Ca2+ Chelators Do Not Block Apoptosis Induced by Other Agents-- It was possible based on the data in Fig. 1 that calcium chelators may block beta -Lap-mediated apoptosis by sequestering calcium required for the activation of apoptotic endonucleases. We, therefore, examined both intra- and extracellular Ca2+ chelators for their ability to prevent apoptosis in NQO1-transfected MDA-468 (MDA-468-NQ3) cells induced by beta -Lap, ionomycin (which induces Ca2+-mediated cell death (36)), and staurosporine (STS, which inhibits protein kinase C and works via a caspase-mediated cell death pathway (43, 44)). We used MDA-468-NQ3 cells to assay for caspase-mediated endonuclease activation and DNA fragmentation since they express the endonuclease-activating caspase 3, unlike MCF-7 cells (45). We previously demonstrated that MDA-468-NQ3 cells responded similarly to beta -Lap as MCF-7 cells (Fig. 2 and Ref. 5). EGTA significantly protected MDA-468-NQ3 cells against ionomycin-induced apoptosis, but not against STS-induced apoptosis (Fig. 2). MDA-468-NQ3 cells treated for 24 h with 10 µM ionomycin exhibited 49% apoptotic cells, whereas, MDA-468-NQ3 cells pretreated for 30 min with 3 mM EGTA followed by a 24-h exposure to ionomycin exhibited only 4% apoptotic cells. Cells treated for 24 h with 1 µM STS in the absence or presence of 3 mM EGTA exhibited 56 and 46% apoptosis, respectively. BAPTA-AM (10 µM) did not significantly block apoptosis induced by ionomycin. BAPTA-AM pretreatment of STS-exposed MDA-468-NQ3 cells did not significantly decrease apoptosis (p < 0.4) compared with cells exposed to STS alone; the modest effect of BAPTA-AM on STS-induced apoptosis may reflect the Ca2+ dependence of the apoptotic endonucleases involved in this response. Neither BAPTA-AM nor EGTA alone elicited apoptotic responses at the doses used in the aforementioned experiments (Figs. 1B and 2). Furthermore, preliminary data suggest that DFF45 (ICAD) was cleaved in NQO1-expressing MCF-7 or MDA-468-NQ3 cells at 8 h after beta -Lap treatment, in a temporal manner corresponding to the induction of apoptosis (data not shown). Cleavage of DFF45, an endogenous inhibitor of the magnesium-dependent and Ca2+-independent apoptotic endonuclease, DFF40 (CAD), suggests that DFF40 is activated following treatment with beta -Lap. Taken together with results in Fig. 1, these data strongly suggest that a rise in intracellular Ca2+ levels is part of a critical signaling pathway for the induction of apoptosis in NQO1-expressing human breast cancer cells following beta -Lap exposure.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 2.   Ca2+ chelators did not block Ca2+-activated endonuclease activation after beta -Lap. NQO1-expressing MDA-468-NQ3 cells (generated from non-expressing human breast cancer cells (5)) were treated with either 3 mM EGTA or 30 µM BAPTA-AM for 30 min prior to drug addition; either a 4-h pulse of 8 µM beta -Lap, or 24 h continuous treatment of 10 µM ionomycin or 1 µM STS. Cells were then analyzed using the TUNEL assay for DNA fragmentation. Shown are mean ± S.E. of at least two independent experiments. Student's t test for paired samples, experimental group compared with cells treated with drug alone are indicated (*, p < 0.05).

Exposure of NQO1-expressing MCF-7 Cells to beta -Lap Results in Increased Intracellular Ca2+-- We next directly examined whether intracellular Ca2+ levels were increased in log-phase MCF-7 cells after beta -Lap treatment using the cell-permeant intracellular Ca2+ indicator dye, fluo-4. Cells were loaded with 5 µM fluo-4-AM, and where indicated, 20 µM BAPTA-AM, incubated for ~25 min to allow for the dye to permeate cells, rinsed, and then incubated for an additional ~20 min for hydrolysis of the AM-ester. Following drug addition, images were collected every 90 s for ~60 min using confocal microscopy. Three basal images were recorded before drug addition and average pixels per cell were determined (indicative of fluo-4 fluorescence and, therefore, basal intracellular Ca2+ levels) and used for analyses over time. The fluorescence of basal images were averaged and set to equal one; fold increases were determined from changes in fluo-4 fluorescence over control.

After exposure to 8 µM beta -Lap, MCF-7 cells exhibited an ~2-fold increase in fluo-4 fluorescence from 4 to 9 min, after which time Ca2+ levels returned to basal levels in a majority of cells examined (43 of 50, 86%) (Fig. 3A). The rise in intracellular Ca2+ levels in MCF-7 cells following beta -Lap exposure was prevented by preloading cells with BAPTA-AM (20 µM) (Fig. 3B). Interestingly, not all beta -Lap-exposed MCF-7 cells were affected by pretreatment with BAPTA-AM; 3 of 26 cells (12%) exhibited a rise in intracellular Ca2+ levels after exposure to beta -Lap despite the presence of this Ca2+ chelator. However, BAPTA-AM pretreated MCF-7 cells that did exhibit a rise in intracellular Ca2+ levels following beta -Lap treatment exhibited a similar, but delayed Ca2+ increase (10-20 min), as compared with beta -Lap-exposed MCF-7 cells in the absence of BAPTA-AM (4-9 min). This may be due to a saturation of the chelator or heterogeneity of the tumor cell population. These results are consistent with previous reports that the buffering capacity of BAPTA-AM may be overwhelmed with time (34, 46). Higher doses of BAPTA-AM were not used due to toxicity caused by the drug alone (data not shown).


View larger version (67K):
[in this window]
[in a new window]
 
Fig. 3.   Intracellular Ca2+ changes after beta -Lap. Intracellular Ca2+ levels were measured in live cells via confocal microscopy using the Ca2+ indicator dye, fluo-4-AM. MCF-7 cells were loaded with either fluo-4-AM alone (A, C, and D) or fluo-4-AM and 20 µM BAPTA-AM (B). beta -Lap (8 µM) was added to cells after basal images were recorded. Images were collected every 90 s for 45-75 min, as indicated. The number in the upper right corner of each Ca2+ image represents the time (min) after beta -Lap addition. A, representative cells before and after beta -Lap treatments are shown as pseudocolored images. These results are also displayed in graph form showing fold change (as compared with basal levels) in fluo-4 fluorescence in cells after beta -Lap treatment over time, with or without co-loading of BAPTA-AM (A and B). C, TG (200 nM) was added to MCF-7 cells after basal images were recorded. Once fluo-4 fluorescence returned to basal levels, cells were subsequently exposed to beta -Lap. D, beta -Lap was added to MCF-7 cells after basal images were recorded. After fluo-4 fluorescence returned to basal levels, TG was subsequently added to the cells. Each line represents the change in fluo-4 fluorescent emission of an individual cell over time; each graph is representative of one of at least three independent experiments.

Since the ER is a major store of Ca2+ in the cell, we tested if the initial rise in intracellular Ca2+ levels after exposure of MCF-7 cells to beta -Lap was due to release of Ca2+ from this organelle. If beta -Lap exposure led to release of Ca2+ stored in the ER, then TG (a sarcoplasmic reticulum Ca2+-ATPase pump inhibitor) administration should not cause additional Ca2+ release. Similarly, if the sequence of drug administration were reversed, additional Ca2+ release would also not be observed. When beta -Lap was added after TG-induced depletion of ER Ca2+ stores, no measurable rise in intracellular Ca2+ levels occurred in 25 of 27 (93%) cells analyzed (Fig. 3C). Similarly, when TG was added to cells after beta -Lap, only 1 of 18 (6%) cells that initially responded to beta -Lap exhibited a rise in intracellular Ca2+ levels following subsequent TG administration (Fig. 3D). At the end of the experiment, all cells analyzed remained responsive to ionomycin. Thus, cells exposed to beta -Lap and/or TG were still capable of altering Ca2+ levels, and the Ca2+ indicator dye was not saturated. We noted that the increase in fluo-4 fluorescence (2-3-fold over basal levels, Fig. 3A) in MCF-7 cells observed after exposure to beta -Lap was comparable to that elicited by TG (1.5-2.5-fold over basal levels, Fig. 3C), further suggesting that the two agents mobilized the same ER pool of Ca2+. All cells analyzed started with comparable basal levels of Ca2+ and appeared to load equal amounts of the indicator dye, as determined by basal fluorescence (measured by pixels per cell) at the beginning of each analysis; relative basal fluo-4 fluorescence for each experiment in Fig. 3 were: A, 56 ± 7; B, 52 ± 7; C, 78 ± 8; D, 79 ± 8 S.E. Untreated or BAPTA-AM-loaded MCF-7 cells did not show any fluctuations in basal Ca2+ levels during the time course of the experiment, nor did any of the drugs interfere with the Ca2+ indicator dye (data not shown).

Loss of Mitochondrial Membrane Potential After beta -Lap Is Attenuated by Intracellular, but Not Extracellular, Ca2+ Chelation-- Mitochondrial membrane potential was previously shown to drop from a hyperpolarized state to a depolarized state after treatment of various human cancer cells with beta -Lap (41). A drop in mitochondrial membrane potential in beta -Lap-treated cells was accompanied by a concomitant release of cytochrome c into the cytosol (41). To explore whether early changes in intracellular Ca2+ levels were upstream of mitochondrial changes in NQO1-expressing breast cancer cells, log phase MCF-7 cells were pretreated for 30 min with either 10 µM BAPTA-AM or 3 mM EGTA and then exposed to 5 µM beta -Lap for 4 h. Prior to analyses, cells were loaded with JC-1, a cationic dye commonly used to monitor alterations in mitochondrial membrane potential (47, 48). Mitochondrial depolarization measurements using JC-1 were indicated by a decrease in the red/green fluorescence intensity ratio (a movement of events from upper left to lower right, Fig. 4), as seen following a 10-min treatment with the potassium ionophore, valinomycin (100 nM), which causes a collapse of mitochondrial membrane potential by uncoupling mitochondrial respiration (Fig. 4e) (49); cells in the upper left-hand quadrant exhibited high mitochondrial membrane potential, whereas, cells in the lower right-hand quadrant have low mitochondrial membrane potential and are depolarized. Cells in the upper right-hand quadrant exhibited intermediate membrane potential. Mitochondrial membrane potential decreased in MCF-7 cells in a time- and dose-dependent manner following exposure to beta -Lap (Figs. 4, a-d, and data not shown). By 4 h, the majority of beta -Lap-treated MCF-7 cells exhibited low mitochondrial membrane potential (53%), while the majority of control cells maintained high mitochondrial membrane potential (51%) (Fig. 4, b, a and g, f, respectively). This drop in mitochondrial membrane potential observed 4 h after treatment with beta -Lap (low, 53%) was abrogated by pretreatment with BAPTA-AM (low, 23%), but not by EGTA (low, 48%) (Fig. 4, g-i, respectively). Pretreatment with 10 µM BAPTA-AM prevented the decrease in mitochondrial membrane potential (low, 23%); however, BAPTA-AM did not maintain beta -Lap-exposed cells in a high-potential state (high, 28%) as observed in control untreated cells (high, 51%). Approximately half of the BAPTA-AM-exposed cells were in an intermediate membrane potential state (45%) (Fig. 4h). We noted, however, that BAPTA-AM or EGTA exposures alone caused depolarization of the mitochondria, with a majority of the cells residing in the same intermediate energized state as observed following BAPTA-AM and beta -Lap (Fig. 4, j-k). Therefore, BAPTA-AM prevented mitochondrial depolarization induced by beta -Lap to the same extent as in cells treated with BAPTA-AM alone. Pretreatment with 3 mM EGTA did not affect the loss of mitochondrial membrane potential caused by beta -Lap (low 48%), implying that an early rise in intracellular Ca2+ levels from intracellular stores was sufficient to cause a drop in mitochondrial membrane potential, and that extracellular calcium was not needed for these effects in beta -Lap-treated cells (Fig. 4, h-i).


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 4.   beta -Lap-induced loss of mitochondrial membrane potential is mediated by alterations in Ca2+ homeostasis. Mitochondrial membrane potential was measured in control or drug-treated MCF-7 cells with the JC-1 dye. A, cells were treated with 5 µM beta -Lap and assayed for changes in mitochondrial membrane potential at 1, 2, and 4 h post-treatment. Exposure of MCF-7 cells to 100 nM valinomycin for 15 min served as a positive control as described (49). Cells in the upper left-hand quadrant exhibit high mitochondrial membrane potential, while cells in the lower right-hand quadrant exhibit low mitochondrial membrane potential. B, cells were treated for 30 min with either 10 µM BAPTA-AM or 3 mM EGTA prior to a 4-h treatment with 5 µM beta -Lap. At 4 h, cells were harvested for analyses of changes in mitochondrial membrane potential using JC-1 as described above. Shown are representative experiments performed at least three times, and numbers in each quadrant represent the average of cells in that quadrant of at least three independent experiments. S.E. for any single number was not more than 11%.

Loss of ATP After beta -Lap Is Attenuated by Intracellular Ca2+ Chelation-- The bioactivation of beta -Lap by NQO1 is thought to lead to a futile cycling between quinone and hydroquinone forms of the compound, presumably due to the instability of the hydroquinone form of beta -Lap (5). This futile cycling led to depletion of NADH and NADPH, electron donors for NQO1 in in vitro assays (5). Exhaustion of reduced enzyme co-factors may be a critical event for the activation of the apoptotic pathway in NQO1-expressing cells following beta -Lap exposure. We, therefore, measured intracellular ATP and ADP in log-phase MCF-7 cells after various doses and times of beta -Lap (using a luciferase-based bioluminescent assay (42)). Intracellular ATP levels were reduced in MCF-7 cells after treatment with beta -Lap in a dose- and time-dependent manner (Fig. 5A). At all doses of beta -Lap above the LD50 of the drug (~2.5 µM) in MCF-7 cells (2), intracellular ATP levels were reduced by >85% at 4 h, the time at which drug was removed (Fig. 5A, left); the loss of ATP correlated well with beta -Lap-induced cell death in MCF-7 cells (Fig. 1C). ADP levels remained relatively unchanged after various doses of beta -Lap, however, the [ATP]/[ADP][Pi] ratio decreased dramatically. Intracellular ATP levels began to drop to 70% of control levels 2 h after 5 µM beta -Lap exposure, the time at which beta -Lap began to elicit mitochondrial membrane depolarization (Figs. 5, A, right, and 4, c). ATP levels continued to drop to 8% of control levels by 4 h after drug exposure (Fig. 5A, right). In contrast, ADP levels remained relatively unchanged during the course of the experiment, with an increase at 30 min (172% control levels) that returned to control levels by 1 h post-treatment. Cellular ATP levels in beta -Lap-treated cells did not appear to recover to normal levels within the 6-24-h interval after drug removal (data not shown).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 5.   ATP depletion after beta -Lap treatment is Ca2+ dependent. Intracellular ATP and ADP levels were measured using a luciferase-based bioluminescent assay. A, cells were treated with the indicated dose of beta -Lap for 4 h or were treated with 5 µM beta -Lap for the time indicated, and harvested for ATP analyses. ATP levels were expressed as nanomoles of ATP per 106 cells. Purified ATP was used as a standard to determine intracellular ATP concentrations. B, cells were either pretreated or untreated with the indicated Ca2+ chelators for 30 min prior to drug addition, and beta -Lap (5 µM) was then added for 4 h. Cells were harvested for analyses following beta -Lap exposure. Results represent the average of at least three independent experiments, ± S.E. Student's t test for paired samples, experimental group compared with drug alone are indicated (*, p < 0.05; **, p < 0.01).

Loss of ATP following beta -Lap was prevented by a 30-min pretreatment with an intracellular Ca2+ chelator, but not an extracellular Ca2+ chelator (Fig. 5B). At 4 h, pretreatment with 10 or 30 µM BAPTA-AM elicited only 58 and 43% ATP loss, respectively, compared with beta -Lap alone (92% loss). The extracellular Ca2+ chelator, EGTA, did not significantly affect the loss of ATP, nor [ATP]/[ADP][Pi] ratio observed in MCF-7 cells after beta -Lap treatment (Fig. 5B). Exposure of MCF-7 cells to TG (200 nM) did not elicit decreases in ATP or ADP levels 4 h after drug exposure, compared with untreated control cells.

Ca2+ Chelators Prevent beta -Lap-induced Proteolysis-- We previously showed that apoptosis in various breast cancer cell lines induced by beta -Lap was unique, causing a pattern of PARP and p53 intracellular cleavage events distinct from those induced by caspase activating agents (12). After beta -Lap treatment, we observed an ~60-kDa PARP cleavage fragment and specific cleavage of p53 in NQO1-expressing breast cancer cells. Furthermore, we showed that this proteolysis in beta -Lap-treated cells was the result of activation of a Ca2+-dependent protease with properties similar to µ-calpain (12). PARP and p53 proteolysis in beta -Lap-exposed, NQO1-expressing cells was prevented by pretreatment with the extracellular Ca2+ chelators, EGTA and EDTA, in a dose-dependent manner (at 8 and 24 h) (Ref. 12, and data not shown). Additionally, PARP, p53, and lamin B proteolysis induced at 24 h in MCF-7 cells following beta -Lap treatment were abrogated by pretreatment with 10 or 30 µM BAPTA-AM (Fig. 6). These data strongly suggest that a Ca2+-dependent pathway and potentially a Ca2+-dependent protease are operative in beta -Lap-mediated apoptosis.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 6.   Intracellular Ca2+ chelators prevent apoptotic proteolysis after beta -Lap treatment. Apoptotic proteolysis was measured in MCF-7 cells exposed to a 4-h pulse of 5 µM beta -Lap, with or without a 30-min pretreatment of the indicated dose of BAPTA-AM. Whole cell extracts were prepared 24 h after drug addition, and analyzed using standard Western blotting techniques with antibodies to PARP, p53, and lamin B. Shown is a representative Western blot of whole cell extracts from experiments performed at least three times.

A simple explanation for the aforementioned results could be that BAPTA blocks bioactivation of beta -Lap by NQO1 in a manner similar to that of dicumarol (5). However, BAPTA (free acid) did not affect the enzymatic activities of NQO1 using standard enzymatic assays (data not shown) (5). The free acid (active) form of BAPTA, instead of its -AM ester form, was used in these assays since intracellular accumulation of this Ca2+ chelator was not necessary and was physiologically relevant in the in vitro enzyme assay. Using beta -Lap as a substrate, NQO1 enzymatic activity in the presence of 10 mM BAPTA (a dose of the free acid form of BAPTA that was >1000-fold higher than that used in the experiments of Figs. 1-6) was reduced by <20%. Thus, BAPTA-AM did not affect the activity of NQO1, a two-electron reductase required for beta -Lap cytotoxicity (5). We conclude that BAPTA-AM prevents beta -Lap-induced apoptosis by blocking Ca2+-mediated signaling events via chelating intracellular Ca2+.

beta -Lap Bioactivation by NQO1 Is Critical for Ca2+-mediated Signaling-- We previously reported that cells expressing NQO1 are more sensitive to the cytotoxic effects of beta -Lap (5).2 NQO1 is inhibited by dicumarol, which competes with NADH or NADPH for binding to the oxidized form of the enzyme. Dicumarol thereby prevents reduction of quinones (50, 51). We demonstrated that dicumarol attenuates beta -Lap-mediated proteolysis of apoptotic substrates (e.g. PARP and p53), apoptosis, and survival in NQO1-expressing cells (5).2 As expected, increases in intracellular Ca2+ levels in NQO1-expressing human cancer cells elicited by beta -Lap were abrogated by co-treatment with 50 µM dicumarol in 26 of 27 cells (96%) examined (Fig. 7A, lower panel). The ability of dicumarol to inhibit increases in intracellular Ca2+ levels was greater than that observed with BAPTA-AM, where intracellular Ca2+ level increases were prevented in only 89% of cells examined (Fig. 3B). Thus, NQO1 was critical for the rise in intracellular Ca2+ levels observed in MCF-7 cells after beta -Lap exposure.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 7.   NQO1-dependent activation of beta -Lap is critical for Ca2+ signaling. A, intracellular Ca2+ was measured on live cells using the Ca2+ indicator dye, fluo-4-AM, and confocal microscopy as described in the legend to Fig. 3. Three basal images were recorded before drug treatments. beta -Lap (8 µM) was then added to MCF-7 cells, either alone (upper panel) or in combination with 50 µM dicumarol (lower panel). Images were collected every 90 s for 50-60 min. Shown are representative graphs displaying changes in fluo-4 fluorescence for the duration of the experiment. Each line represents the fold change in fluo-4 fluorescent emission (as compared with basal levels) of an individual cell from one experiment, and the graph is representative of experiments performed at least three times. B, mitochondrial membrane potential was measured using the JC-1 dye as described in the legend to Fig. 4. MCF-7 cells were treated with 50 µM dicumarol 30 min prior to beta -Lap exposure. Four hours later, cells were harvested for analyses of mitochondrial membrane potential. Shown are mean ± S.E. of the percentage of cells with low mitochondrial membrane potential of at least two independent experiments. C, ATP and ADP levels were assayed as described in the legend to Fig. 5. Cells were pretreated with dicumarol for 30 min prior to drug addition, 5 µM beta -Lap was added for 4 h, and cells were harvested immediately thereafter for analyses. Results represent the mean of at least three independent experiments ± S.E. Student's t test for paired samples, experimental groups compared with drug alone are indicated (* p < 0.05). D, apoptosis, using the TUNEL assay, was assessed as per Fig. 1. MCF-7 cells were treated with 50 µM dicumarol 30 min prior to a 4-h exposure of 5 µM beta -Lap. Cells were then harvested for TUNEL analyses at 24 h post-treatment. Shown are mean ± S.E. of at least three independent experiments. Student's t test for paired samples, experimental groups compared with beta -Lap exposure alone are indicated (*, p < 0.005). DC, 50 µM dicumarol.

Mitochondrial membrane depolarization induced by beta -Lap was also abrogated by pretreatment with dicumarol (Fig. 7B). By 4 h, the majority of beta -Lap-treated cells exhibited low mitochondrial membrane potential (58%), while very few control cells were depolarized (9%) (Fig. 7B). Pretreatment with dicumarol attenuated this response to beta -Lap, with only 34% being depolarized. The inability of dicumarol to prevent mitochondrial depolarization in 34% of beta -Lap-treated cells was probably due to the high background of control cells (20%) that were depolarized after exposure to dicumarol alone. In comparison with intracellular Ca2+ buffering, BAPTA-AM elicited only a minor depolarization of the mitochondria on its own (low, 14%) and thus was able to elicit a greater protective effect (Fig. 4B); only 23% of cells exposed to BAPTA-AM and beta -Lap exhibited low mitochondrial membrane potential as compared with beta -Lap exposed cells in the presence of dicumarol (34%).

The dramatic loss of intracellular ATP in MCF-7 cells following beta -Lap exposure was inhibited by a 30-min pretreatment with 50 µM dicumarol (Fig. 7C). beta -Lap-treated MCF-7 cells pretreated with dicumarol exhibited only 34% loss of intracellular ATP, compared with 92% loss after beta -Lap treatment alone (Fig. 7C). ADP levels were not altered by any of the treatments used, however, the [ATP]/[ADP][Pi] ratio decreased dramatically in beta -Lap-treated cells, and was only partially decreased with dicumarol pretreatment alone, as compared with control untreated cells.

Dicumarol also abrogated DNA fragmentation induced by beta -Lap in MCF-7 cells. MCF-7 cells exhibited 94% apoptosis following beta -Lap exposure that was prevented by a 30-min pretreatment with 50 µM dicumarol; only 6% of the cells staining positive in a TUNEL assay at 24 h post-treatment (Fig. 7D). These data are consistent with prior results (5), and correlate well with the survival protection afforded by dicumarol to beta -Lap-treated cells. Dicumarol did not induce DNA fragmentation on its own. These data are consistent with the protection from apoptosis observed with either intra- and extracellular Ca2+ chelators. BAPTA-AM or EGTA protected beta -Lap exposed MCF-7 cells from apoptosis (Fig. 1, A and B). Collectively, these data implicate the bioactivation of beta -Lap by NQO1 as a critical step in the rise of intracellular Ca2+ levels following beta -Lap exposure, and thus beta -Lap-mediated downstream apoptotic events.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

When homeostatic mechanisms for regulating cellular Ca2+ are compromised, cells may die, either by necrosis or apoptosis (20, 21, 36). We demonstrated that bioactivation of beta -Lap by NQO1 induced cell death in a manner that was dependent upon Ca2+ signaling (Figs. 1-6). beta -Lap can be reduced by NQO1 and may undergo futile cycling between quinone and hydroquinone forms (beta -Lap-Q and beta -Lap-HQ, Fig. 8), presumably depleting NADH and/or NADPH in the cell (5). We theorize that depletion of NAD(P)H, along with a rise in intracellular Ca2+ levels in response to beta -Lap, activate a novel caspase-independent apoptotic pathway, as described in this paper and previously (2, 5, 12). The rise in intracellular Ca2+ appears to be dependent upon the bioactivation of beta -Lap by NQO1, suggesting a critical and necessary signaling role for Ca2+ in the downstream apoptotic pathway induced by this drug. Dicumarol completely abrogated intracellular Ca2+ changes (Fig. 7), as well as apoptosis and survival, following beta -Lap exposure of NQO1-expressing cells (5).2 When increases in intracellular Ca2+ levels were directly prevented by pretreatment with BAPTA-AM, downstream apoptotic responses, as well as lethality, caused by beta -Lap were prevented; when corrected for BAPTA-AM affects alone, beta -Lap-induced apoptosis, proteolysis, and lethality were essentially blocked by preventing early Ca2+ release from ER stores. Thus, correcting for the BAPTA-AM affects alone, the role of Ca2+ in beta -Lap-mediated apoptosis may be more significant that that revealed by the data shown. These data strongly suggest that DNA fragmentation, mitochondrial membrane depolarization, ATP loss, and apoptotic proteolysis were a consequence of the increase in intracellular Ca2+ levels (Figs. 1-6 and 8). Interestingly, the cell death pathway induced by beta -Lap was quite distinct from that observed after exposure to TG, an agent known to specifically cause release of Ca2+ from ER stores and mediate caspase-dependent apoptosis (24, 28, 33, 52). Thus, Ca2+ release was necessary for beta -Lap-induced cytotoxicity, but apparently not sufficient for the unique apoptotic responses induced by beta -Lap.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 8.   Proposed model for beta -lapachone-mediated apoptosis in NQO1-expressing cells. In cells that express NQO1, beta -Lap is reduced from the quinone (beta -lap-Q) to the hydroquinone (beta -lap-HQ) form in a futile cycle that results in dramatic losses of NAD(P)H (5). During the metabolism of beta -Lap by NQO1, Ca2+ is subsequently released from the ER causing a rise in cytosolic Ca2+ levels by an as yet unknown mechanism. To maintain low cytoplasmic Ca2+ levels, we theorize that mitochondria sequester Ca2+ and numerous cellular ATPases probably function to pump Ca2+ out of the cytosol. This leads to mitochondrial membrane depolarization and ATP hydrolysis, respectively (Figs. 4 and 5). Sustained depolarization of the mitochondrial membrane leads to further loss of ATP and prevents ATP synthesis by inhibiting respiration. The loss of ATP disrupts ionic homeostasis within the cell and thereby allows extracellular Ca2+ to enter the cell down its concentration gradient (see "Discussion"). The secondary rise in cytosolic Ca2+ levels leads to protease (presumably activation of calpain or a calpain-like protease) and, thus, endonuclease (DFF40) activation, ultimately resulting in apoptosis.

beta -Lap and TG-induced Similar Ca2+ Responses, but Different Patterns of Apoptosis-- beta -Lap elicited an early rise in intracellular Ca2+ levels from the same ER store as released by TG, however, subsequent cell death processes were remarkably different between the two compounds. TG is known to cause transient increases in intracellular Ca2+ levels, however, these were insufficient to induce apoptosis. Much like beta -Lap, Ca2+ was needed from the extracellular milieu, along with a sustained increase in intracellular Ca2+ levels, for TG-induced apoptosis (23) in MCF-7 cells (27). Depolarization of the mitochondrial membrane potential and loss of intracellular ATP in cells exposed to beta -Lap, may have prevented plasma membrane Ca2+ pumps and ER Ca2+ pumps from functioning and maintaining Ca2+ homeostasis. This, in turn, may have facilitated Ca2+ leakage down its concentration gradient into the cytosol, providing a secondary and sustained elevation of Ca2+ that initiated a protease cascade(s) and ultimately caused apoptosis after exposure to beta -Lap. This is consistent with what we observed in NQO1-expressing cells after beta -Lap treatment and co-administration of Ca2+ chelators. Buffering intracellular Ca2+ with BAPTA-AM partially abrogated all of the downstream events induced in MCF-7 cells by beta -Lap (and thus prevented secondary Ca2+ entry by buffering the initial rise in cytosolic Ca2+). In contrast, extracellular chelation by EGTA only prevented those events initiated by secondary Ca2+ entry (e.g. protease activation and DNA fragmentation). Thus, a secondary rise in intracellular Ca2+ levels after exposure to beta -Lap seems probable, and necessary, for protease activation and DNA fragmentation as was observed for TG-induced caspase-mediated apoptosis (23, 27). However, a secondary influx of Ca2+ does not appear to be necessary for reduction in mitochondrial membrane potential or loss of intracellular ATP after beta -Lap exposure, since EGTA did not prevent these responses.

Although MCF-7 cells treated with beta -Lap had similar calcium responses, as do TG-exposed cells, beta -Lap-exposed cells exhibited a very different pattern of apoptosis than TG-treated cells. beta -Lap-exposed cells exhibit loss of intracellular ATP and a decrease in the [ATP]/[ADP][Pi] ratio. In contrast, TG-exposed cells did not exhibit loss of ATP (Fig. 5, and as reported by Ref. 53). Our data suggest that in contrast to TG where ATP-dependent caspase activation results in cell death (28, 33, 34, 54), an ATP-independent protease is activated after exposure to beta -Lap. Ca2+ may regulate apoptosis by activating Ca2+-dependent protein kinases and/or phosphatases leading to alterations in gene transcription. However, with the rapid loss of intracellular ATP after exposure to beta -Lap (2-4 h, Fig. 5), beta -Lap-mediated cell death unlikely involves stimulated kinases or phosphatases or new protein synthesis. Instead, indirect kinase inhibition, due to ATP depletion, along with continued phosphatase activity is likely. Consistent with this notion, we found dramatic de-phosphorylation of pRb in cells exposed to beta -Lap at 3 h (2), a time consistent with loss of ATP following exposure to this drug. Furthermore, loss of ATP at 2 h may also be responsible for inhibition of NF-kappa B activation induced by tumor necrosis factor-alpha in beta -Lap pre-exposed cells (55), since significant loss of ATP would prevent proteosome-mediated Ikappa B degradation. Thus, Ca2+-dependent loss of ATP in NQO1-expressing cells following beta -Lap treatment may explain the reported pleiotropic effects of this agent.

beta -Lap-exposed cells also exhibited a very different pattern of substrate proteolysis compared with that observed after TG (2, 12, 28). We previously showed that beta -Lap elicited a unique cleavage of PARP (~60-kDa fragment), compared with the classical caspase-3-mediated fragmentation of the protein (~89 kDa) observed after TG exposure (data not shown and Ref. 28). In a variety of NQO1-expressing cells exposed to beta -Lap, atypical PARP cleavage was inhibited by the global cysteine protease inhibitors, iodoacetamide and N-ethylmaleimide, as well as the extracellular Ca2+ chelators, EGTA and EDTA (12). In addition, beta -Lap-mediated apoptotic responses were insensitive to inhibitors of caspases, granzyme B, cathepsins B and L, trypsin, and chymotrypsin-like proteases (12). In contrast, classic caspase inhibitors blocked TG-induced caspase activation and apoptosis (28). Caspase activation, as measured by pro-caspase cleavage via Western blot analyses, does not occur following beta -Lap exposures.3 Thus, protease activation after beta -Lap treatment appears to be Ca2+-dependent, or alternatively, is activated by another protease or event that is Ca2+-dependent (Figs. 1-6 and Ref. 12).

Loss of Reducing Equivalents Is Also Necessary for beta -Lap-mediated Apoptosis, Similar to Menadione-mediated Apoptosis-- Menadione is a quinone that can be detoxified by NQO1 two-electron reduction. However, menadione can also be reduced through two, one-electron reductions via other cellular reductases (56), thus eliciting menadione's toxic effects. Menadione toxicity, elicited via two, one-electron reductions, exhibited many similarities to beta -Lap-mediated, NQO1-dependent, toxicity (5). These included: (a) elevations in cytosolic Ca2+ (57, 58); (b) NAD(P)H depletion (5, 59, 60); (c) ATP depletion (<0.1% control)3 (61-63); and (d) mitochondrial membrane potential depolarization3 (64). We previously demonstrated that menadione caused similar substrate proteolysis (p53 and atypical PARP cleavage) in NQO1-deficient cells, or at high doses in cells that express NQO1 where detoxification processes were over-ridden (5).3 The semiquinone form of menadione can undergo spontaneous oxidation to the parent quinone (59, 63, 65, 66); a pattern similar to the futile cycling observed after beta -Lap bioactivation by NQO1 (5). Loss of reducing equivalents, such as NADH, due to the futile cycling of menadione may cause inactivation of the electron transport chain with the concomitant loss of mitochondrial membrane potential, and thus, loss of ATP (67, 68). These responses were also observed in MCF-7 cells exposed to beta -Lap (Figs. 4 and 5). Extensive mitochondrial Ca2+ accumulation can also mediate mitochondrial depolarization (69, 70). Thus, Ca2+ sequestration may elicit mitochondrial membrane depolarization and consequent ATP depletion in cells exposed to beta -lap. These data further suggest that Ca2+ is necessary for beta -Lap-mediated cell death, but other factors are apparently needed for the initiation of the novel execution apoptotic pathway observed in cells treated with this compound.

The rise in intracellular Ca2+ appears to be dependent on the bioactivation of beta -Lap by NQO1, suggesting a critical and necessary signaling role for Ca2+ in the downstream apoptotic pathway induced by this drug. These data suggest that DNA fragmentation, mitochondrial membrane depolarization, ATP loss, and apoptotic proteolysis were a consequence of the increase in intracellular Ca2+ levels. Work in our laboratory is focused on elucidating the signaling response(s) that elicits ER Ca2+ release following beta -Lap bioactivation by NQO1. The cell death pathway induced by beta -Lap is quite distinct from that observed after exposure to TG, and beta -Lap-mediated apoptosis exhibited many similarities to menadione-mediated apoptosis. These observations further suggest that early release of Ca2+ from ER stores, as well as influx of Ca2+ from the extracellular milieu are necessary, but not sufficient for the novel apoptotic execution pathway induced by beta -Lap. Thus, changes in Ca2+ homeostasis in conjunction with the presumed loss of reducing equivalents are both necessary and sufficient for beta -Lap-mediated apoptosis. We propose that development of beta -Lap for treatment of human cancers that have elevated NQO1 levels (e.g. breast and lung) is warranted (6). Since most clinical agents used to date kill cells by caspase-dependent and p53-dependent pathways, and many cancers evade death by altering these pathways, development of agents that kill by specific targets (NQO1-mediated) and in p53- and caspase-independent manners are needed.

    ACKNOWLEDGEMENTS

We thank Sara Simmers and Rich Tarin for all their technical help, as well as R. Michael Sramkoski, MT-(ASCP)H. We are grateful to Dr. William G. Bornmann for synthesizing beta -lapachone, and Edmunds Z. Reineks and Philip A. Verhoef for critical review of this manuscript. We are also indebted to Sarah Hildebrand for her enduring support of our research.

    FOOTNOTES

* This work was supported by United States Army Medical Research and Materiel Command Breast Cancer Initiative Grant DAMD17-98-1-8260 (to D. A. B.), Predoctoral Fellowship DAMD17-00-1-0194 (to C. T.), and Postdoctoral Fellowship DAMD-17-97-1-7221 (to J. J. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Partial fulfillment of the requirements for the Ph.D. degree, Case Western Reserve University, Dept. of Pharmacology.

** To whom correspondence should be addressed: Dept. of Radiation Oncology (BRB-326 East), Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106-4942. Tel.: 216-368-0840; Fax: 216-368-1142; E-mail: dab30@po.cwru.edu.

Published, JBC Papers in Press, March 2, 2001, DOI 10.1074/jbc.M100730200

2 S. M. Planchon, C. Tagliarino, J. J. Pink, W. G. Bornmann, M. E. Varnes, and D. A. Boothman. Exp. Cell Res., in press.

3 C. Tagliarino, J. J. Pink, and D. A. Boothman, unpublished results.

    ABBREVIATIONS

The abbreviations used are: beta -Lap, beta -lapachone; MCP, MCF-7:WS8; NQO1, NAD(P)H:quinone oxidoreductase, DT-diaphorase (E.C. 1.6.99.2); PARP, poly(ADP-ribose) polymerase; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling; ER, endoplasmic reticulum; TG, thapsigargin; STS, staurosporine; BAPTA-AM, 1,2-bis-(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Planchon, S. M., Wuerzberger, S., Frydman, B., Witiak, D. T., Hutson, P., Church, D. R., Wilding, G., and Boothman, D. A. (1995) Cancer Res. 55, 3706-3711[Abstract]
2. Wuerzberger, S. M., Pink, J. J., Planchon, S. M., Byers, K. L., Bornmann, W. G., and Boothman, D. A. (1998) Cancer Res. 58, 1876-1885[Abstract]
3. Li, C. J., Wang, C., and Pardee, A. B. (1995) Cancer Res. 55, 3712-3715[Abstract]
4. Li, C. J., Li, Y. Z., Pinto, A. V., and Pardee, A. B. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 13369-13374[Abstract/Free Full Text]
5. Pink, J. J., Planchon, S. M., Tagliarino, C., Varnes, M. E., Siegel, D., and Boothman, D. A. (2000) J. Biol. Chem. 275, 5416-5424[Abstract/Free Full Text]
6. Marin, A., Lopez de Cerain, A., Hamilton, E., Lewis, A. D., Martinez-Penuela, J. M., Idoate, M. A., and Bello, J. (1997) Br. J. Cancer 76, 923-929[Medline] [Order article via Infotrieve]
7. Patel, T., Gores, G. J., and Kaufmann, S. H. (1996) FASEB J. 10, 587-597[Abstract/Free Full Text]
8. Gerschenson, L. E., and Rotello, R. J. (1992) FASEB J. 6, 2450-2455[Abstract/Free Full Text]
9. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D. (1997) Science 275, 1132-1136[Abstract/Free Full Text]
10. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997) Cell 91, 479-489[Medline] [Order article via Infotrieve]
11. Eguchi, Y., Srinivasan, A., Tomaselli, K. J., Shimizu, S., and Tsujimoto, Y. (1999) Cancer Res. 59, 2174-2181[Abstract/Free Full Text]
12. Pink, J. J., Wuerzberger-Davis, S., Tagliarino, C., Planchon, S. M., Yang, X., Froelich, C. J., and Boothman, D. A. (2000) Exp. Cell Res. 255, 144-155[CrossRef][Medline] [Order article via Infotrieve]
13. Froelich, C. J., Hanna, W. L., Poirier, G. G., Duriez, P. J., D'Amours, D., Salvesen, G. S., Alnemri, E. S., Earnshaw, W. C., and Shah, G. M. (1996) Biochem. Biophys. Res. Commun. 227, 658-665[CrossRef][Medline] [Order article via Infotrieve]
14. Pariat, M., Carillo, S., Molinari, M., Salvat, C., Debussche, L., Bracco, L., Milner, J., and Piechaczyk, M. (1997) Mol. Cell. Biol. 17, 2806-2815[Abstract]
15. Kubbutat, M. H., and Vousden, K. H. (1997) Mol. Cell. Biol. 17, 460-468[Abstract]
16. Distelhorst, C. W., and Dubyak, G. (1998) Blood 91, 731-734[Free Full Text]
17. Fang, M., Zhang, H., Xue, S., Li, N., and Wang, L. (1998) Cancer Lett. 127, 113-121[CrossRef][Medline] [Order article via Infotrieve]
18. Marks, A. R. (1997) Am. J. Physiol. 272, H597-605[Abstract/Free Full Text]
19. McConkey, D. J., Hartzell, P., Amador-Perez, J. F., Orrenius, S., and Jondal, M. (1989) J. Immunol. 143, 1801-1806[Abstract/Free Full Text]
20. McConkey, D. J., and Orrenius, S. (1997) Biochem. Biophys. Res. Commun. 239, 357-366[CrossRef][Medline] [Order article via Infotrieve]
21. McConkey, D. J. (1996) Scanning Microsc. 10, 777-793[Medline] [Order article via Infotrieve]
22. Martikainen, P., and Isaacs, J. (1990) Prostate 17, 175-187[Medline] [Order article via Infotrieve]
23. Jiang, S., Chow, S. C., Nicotera, P., and Orrenius, S. (1994) Exp. Cell Res. 212, 84-92[CrossRef][Medline] [Order article via Infotrieve]
24. Kaneko, Y., and Tsukamoto, A. (1994) Cancer Lett. 79, 147-155[Medline] [Order article via Infotrieve]
25. Levick, V., Coffey, H., and D'Mello, S. R. (1995) Brain Res 676, 325-335[CrossRef][Medline] [Order article via Infotrieve]
26. Choi, M. S., Boise, L. H., Gottschalk, A. R., Quintans, J., Thompson, C. B., and Klaus, G. G. (1995) Eur. J. Immunol. 25, 1352-1357[Medline] [Order article via Infotrieve]
27. Jackisch, C., Hahm, H. A., Tombal, B., McCloskey, D., Butash, K., Davidson, N. E., and Denmeade, S. R. (2000) Clin. Cancer Res. 6, 2844-2850[Abstract/Free Full Text]
28. McColl, K. S., He, H., Zhong, H., Whitacre, C. M., Berger, N. A., and Distelhorst, C. W. (1998) Mol. Cell. Endocrinol. 139, 229-238[CrossRef][Medline] [Order article via Infotrieve]
29. Yakovlev, A. G., Wang, G., Stoica, B. A., Boulares, H. A., Spoonde, A. Y., Yoshihara, K., and Smulson, M. E. (2000) J. Biol. Chem. 275, 21302-21308[Abstract/Free Full Text]
30. Gaido, M. L., and Cidlowski, J. A. (1991) J. Biol. Chem. 266, 18580-18585[Abstract/Free Full Text]
31. Urbano, A., McCaffrey, R., and Foss, F. (1998) J. Biol. Chem. 273, 34820-34827[Abstract/Free Full Text]
32. McConkey, D. J., Nicotera, P., Hartzell, P., Bellomo, G., Wyllie, A. H., and Orrenius, S. (1989) Arch Biochem. Biophys. 269, 365-370[Medline] [Order article via Infotrieve]
33. Srivastava, R. K., Sollott, S. J., Khan, L., Hansford, R., Lakatta, E. G., and Longo, D. L. (1999) Mol. Cell. Biol. 19, 5659-5674[Abstract/Free Full Text]
34. Wertz, I. E., and Dixit, V. M. (2000) J. Biol. Chem. 275, 11470-11477[Abstract/Free Full Text]
35. Lotem, J., and Sachs, L. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4601-4606[Abstract/Free Full Text]
36. Petersen, A., Castilho, R. F., Hansson, O., Wieloch, T., and Brundin, P. (2000) Brain Res. 857, 20-29[CrossRef][Medline] [Order article via Infotrieve]
37. Green, D. R., and Reed, J. C. (1998) Science 281, 1309-1312[Abstract/Free Full Text]
38. Kroemer, G., Dallaporta, B., and Resche-Rigon, M. (1998) Annu. Rev. Physiol. 60, 619-642[CrossRef][Medline] [Order article via Infotrieve]
39. Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., Larochette, N., Goodlett, D. R., Aebersold, R., Siderovski, D. P., Penninger, J. M., and Kroemer, G. (1999) Nature 397, 441-446[CrossRef][Medline] [Order article via Infotrieve]
40. Richter, C. (1993) FEBS Lett. 325, 104-107[CrossRef][Medline] [Order article via Infotrieve]
41. Li, Y. Z., Li, C. J., Pinto, A. V., and Pardee, A. B. (1999) Mol. Med. 5, 232-239[Medline] [Order article via Infotrieve]
42. Beigi, R. D., and Dubyak, G. R. (2000) J. Immunol. 165, 7189-7198[Abstract/Free Full Text]
43. Tang, D., Lahti, J. M., and Kidd, V. J. (2000) J. Biol. Chem. 275, 9303-9307[Abstract/Free Full Text]
44. Kim, J. E., Oh, J. H., Choi, W. S., Chang, I. I., Sohn, S., Krajewski, S., Reed, J. C., O'Malley, K. L., and Oh, Y. J. (1999) J. Neurochem. 72, 2456-2463[CrossRef][Medline] [Order article via Infotrieve]
45. Kurokawa, H., Nishio, K., Fukumoto, H., Tomonari, A., Suzuki, T., and Saijo, N. (1999) Oncol. Rep. 6, 33-37[Medline] [Order article via Infotrieve]
46. Yao, Y., and Tsien, R. Y. (1997) J. Gen. Physiol. 109, 703-715[Abstract/Free Full Text]
47. Cossarizza, A., Baccarani-Contri, M., Kalashnikova, G., and Franceschi, C. (1993) Biochem. Biophys. Res. Commun. 197, 40-45[CrossRef][Medline] [Order article via Infotrieve]
48. Salvioli, S., Ardizzoni, A., Franceschi, C., and Cossarizza, A. (1997) FEBS Lett. 411, 77-82[CrossRef][Medline] [Order article via Infotrieve]
49. Inai, Y., Yabuki, M., Kanno, T., Akiyama, J., Yasuda, T., and Utsumi, K. (1997) Cell Struct. Funct. 22, 555-563[Medline] [Order article via Infotrieve]
50. Hollander, P. M., and Ernster, L. (1975) Arch. Biochem. Biophys. 169, 560-567[Medline] [Order article via Infotrieve]
51. Hosoda, S., Nakamura, W., and Hayashi, K. (1974) J. Biol. Chem. 249, 6416-6423[Abstract/Free Full Text]
52. Distelhorst, C. W., and McCormick, T. S. (1996) Cell Calcium 19, 473-483[Medline] [Order article via Infotrieve]
53. Waring, P., and Beaver, J. (1996) Exp. Cell Res. 227, 264-276[CrossRef][Medline] [Order article via Infotrieve]
54. Qi, X. M., He, H., Zhong, H., and Distelhorst, C. W. (1997) Oncogene 15, 1207-1212[CrossRef][Medline] [Order article via Infotrieve]
55. Manna, S. K., Gad, Y. P., Mukhopadhyay, A., and Aggarwal, B. B. (1999) Biochem. Pharmacol. 57, 763-774[CrossRef][Medline] [Order article via Infotrieve]
56. Iyanagi, T., and Yamazaki, I. (1970) Biochim. Biophys. Acta 216, 282-294[Medline] [Order article via Infotrieve]
57. Jewell, S. A., Bellomo, G., Thor, H., Orrenius, S., and Smith, M. (1982) Science 217, 1257-1259[Medline] [Order article via Infotrieve]
58. Nicotera, P., McConkey, D., Svensson, S. A., Bellomo, G., and Orrenius, S. (1988) Toxicology 52, 55-63[Medline] [Order article via Infotrieve]
59. Di Monte, D., Bellomo, G., Thor, H., Nicotera, P., and Orrenius, S. (1984) Arch. Biochem. Biophys 235, 343-350[Medline] [Order article via Infotrieve]
60. Smith, P. F., Alberts, D. W., and Rush, G. F. (1987) Toxicol. Appl. Pharmacol. 89, 190-201[Medline] [Order article via Infotrieve]
61. Akman, S. A., Doroshow, J. H., Dietrich, M. F., Chlebowski, R. T., and Block, J. S. (1987) J. Pharmacol. Exp. Ther. 240, 486-491[Abstract]
62. Mehendale, H. M., Svensson, S. A., Baldi, C., and Orrenius, S. (1985) Eur. J. Biochem. 149, 201-206[Abstract]
63. Redegeld, F. A., Moison, R. M., Koster, A. S., and Noordhoek, J. (1989) Arch. Biochem. Biophys. 273, 215-222[CrossRef][Medline] [Order article via Infotrieve]
64. Saxena, K., Henry, T. R., Solem, L. E., and Wallace, K. B. (1995) Arch. Biochem. Biophys. 317, 79-84[CrossRef][Medline] [Order article via Infotrieve]
65. Mirabelli, F., Salis, A., Marinoni, V., Finardi, G., Bellomo, G., Thor, H., and Orrenius, S. (1988) Arch. Biochem. Biophys. 264, 261-269[Medline] [Order article via Infotrieve]
66. Frei, B., Winterhalter, K. H., and Richter, C. (1986) Biochemistry 25, 4438-4443[Medline] [Order article via Infotrieve]
67. Redegeld, F. A., Moison, R. M., Barentsen, H. M., Koster, A. S., and Noordhoek, J. (1990) Arch. Biochem. Biophys. 280, 130-136[Medline] [Order article via Infotrieve]
68. Bellomo, G., Jewell, S. A., and Orrenius, S. (1982) J. Biol. Chem. 257, 11558-11562[Abstract/Free Full Text]
69. Akerman, K. E. (1978) Biochim. Biophys. Acta 502, 359-366[Medline] [Order article via Infotrieve]
70. Budd, S. L., Tenneti, L., Lishnak, T., and Lipton, S. A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 6161-6166[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.